If the filing person has previously filed
a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because
of
§§
240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box. ☐
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
|
1.
|
Names of Reporting Persons. I.R.S. Identification Nos. of Above
Persons (Entities Only):
Thomas Meyer
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See
Instructions):
(a) ☐
(b) ☐
|
|
3.
|
SEC Use Only
|
|
|
|
|
4.
|
Source of Funds (See Instructions):
PF
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required Pursuant
to Items 2(d) or 2(e): ☐
|
|
6.
|
Citizenship or Place of Organization:
Switzerland
|
|
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
|
7.
|
Sole Voting Power:
489,573*
|
|
8.
|
Shared Voting Power:
0
|
|
9.
|
Sole Dispositive Power:
489,573*
|
|
10.
|
Shared Dispositive Power:
0
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person:
489,573*
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): ☐
|
|
13.
|
Percent of Class Represented by Amount in Row (11):
14.4%*
|
|
14.
|
Type of Reporting Person (See Instructions):
IN
|
*The foregoing beneficial
ownership percentage is based upon 3,267,224 common shares, par value CHF 0.40 per share (the “Common Shares”) of
Auris Medical Holding Ltd., a Bermuda corporation (the “Issuer”), issued and outstanding as of June 3, 2019, based
on information from the Issuer. Reporting Person beneficially owns 489,573 Common Shares consisting of 350,000 Common Shares and
warrants and options to purchase up to 139,573 Common Shares exercisable within 60 days of the date hereof.
Explanatory Note
This Amendment No.
3 (the “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Person (as defined in the Schedule
13D) with the Securities and Exchange Commission (the “SEC”) on November 21, 2018 (the “Schedule 13D”).
Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the
Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule
13D.
|
|
Item 1.
|
Security and Issuer
|
Item 1 of the Schedule
13D is hereby amended by deleting it in its entirety and substituting the following in lieu thereof:
This Schedule 13D, as
amended by this Amendment relates to common shares, par value CHF 0.40 per share (the “Common Shares”) of Auris Medical
Holding Ltd., a Bermuda corporation (the “Issuer”). The principal executive offices of the Issuer are located at Clarendon
House, 2 Church Street, Hamilton HM 11.
|
|
Item 2.
|
Identity and Background
|
Item 2 of the Schedule
13D is hereby amended by deleting it in its entirety and substituting the following in lieu thereof:
|
|
(a)
|
This Statement is being filed on behalf of Thomas Meyer (the “
Reporting Person
”).
|
|
|
(b)
|
The principal business address of the Reporting Person is Clarendon House, 2 Church Street, Hamilton HM 11.
|
|
|
(c)
|
The present occupation of the Reporting Person is Chairman and Chief Executive Officer of the Issuer. The Issuer’s
principal business address is Clarendon House, 2 Church Street, Hamilton HM 11, and its principal business is the development
of therapeutics that address important unmet medical needs in neurotology and central nervous system disorders.
|
|
|
(d)
|
The Reporting Person has not has been convicted in a criminal proceeding (excluding traffic violations
or similar misdemeanors) in the past five years.
|
|
|
(e)
|
The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final
order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding
any violation with respect to such laws.
|
|
|
(f)
|
The Reporting Person is a citizen of Switzerland.
|
|
|
Item 3.
|
Source and Amount of Funds or Other Consideration
|
Item 3 of the Schedule
13D is hereby amended by deleting it in its entirety and substituting the following in lieu thereof:
On June 3, 2019, the Reporting
Person purchased 1,000 Common Shares at a purchase price of $2.72 per share for a total of $2,720.00. Reporting Person purchased
these Common Shares with personal funds.
On June 3, 2019, the Reporting
Person purchased 6,000 Common Shares at a purchase price of $2.71 per share for a total of $16,260.00. Reporting Person purchased
these Common Shares with personal funds.
On June 3, 2019, the
Reporting Person purchased 9,729 Common Shares at a purchase price of $2.80 per share for a total of $27,241.20. Reporting Person
purchased these Common Shares with personal funds.
On June 4, 2019, the
Reporting Person purchased 1,000 Common Shares at a purchase price of $2.50 per share for a total of $2,500.00. Reporting Person
purchased these Common Shares with personal funds.
On June 4, 2019, the
Reporting Person purchased 5,000 Common Shares at a purchase price of $2.49 per share for a total of $12,450.00. Reporting Person
purchased these Common Shares with personal funds.
On June 4, 2019, the
Reporting Person purchased 2,000 Common Shares at a purchase price of $2.53 per share for a total of $5,060.00. Reporting Person
purchased these Common Shares with personal funds.
On June 4, 2019, the
Reporting Person purchased 5,000 Common Shares at a purchase price of $2.55 per share for a total of $12,750.00. Reporting Person
purchased these Common Shares with personal funds.
On June 4, 2019, the
Reporting Person purchased 5,000 Common Shares at a purchase price of $2.51 per share for a total of $12,550.00. Reporting Person
purchased these Common Shares with personal funds.
On June 5, 2019, the
Reporting Person purchased 5,000 Common Shares at a purchase price of $2.85 per share for a total of $14,250.00. Reporting Person
purchased these Common Shares with personal funds.
The Reporting Person
did not borrow any funds to effectuate the transactions whereby he received the securities that are the subject of this filing
on Schedule 13D.
|
|
Item 4.
|
Purpose of Transaction
|
Item 4 of the Schedule
13D is hereby amended by deleting it in its entirety and substituting the following in lieu thereof:
The Reporting Persons
acquired the securities reported herein for investment. Currently, Reporting Person is the Chief Executive Officer and Director
of the Issuer. As of June 13, 2019 (“
Filing Date
”), the Reporting Person beneficially owns 489,573 Common Shares
including Common Shares that the Reporting Person has the right to acquire within 60 days of the Filing Date upon exercise of
outstanding options and warrants.
Except as set forth
herein and to the extent the foregoing may be deemed a plan or proposal, the Reporting Person does not have plans or proposals
which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions
to Item 4 of Schedule 13D.
|
|
Item 5.
|
Interest in Securities of the Issuer
|
Item 5 of the Schedule
13D is hereby amended by deleting it in its entirety and substituting the following in lieu thereof:
|
|
(a)
|
The information contained on the cover pages to this Schedule 13D/A is hereby incorporated herein by reference.
As of the Filing Date there are 3,267,224 Common Shares outstanding. The Reporting Person beneficially owns 489,573 Common Shares
including Common Shares that the Reporting Person has the right to acquire within 60 days of the Filing Date upon exercise of outstanding
options and warrants.
|
|
|
(b)
|
The Reporting Person holds sole power to vote and dispose over all of the Common Shares of the
Issuer that he beneficially owns.
|
|
|
(c)
|
The information provided in Item 3 and Item 4 is incorporated by reference herein.
|
Except as described herein, during the past
sixty (60) days on or prior to June 13, 2019 (the “
Event Date
”), and from the Event Date to the Filing Date,
there were no other purchases or sales of Common Shares, or securities convertible into or exchangeable for Common Shares, by
the Reporting Persons or any person or entity for which the Reporting Persons possess voting or dispositive control over the securities
thereof.
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: June 13, 2019
|
|
/s/ Thomas Meyer
|
|
|
Thomas Meyer
|
Attention: Intentional misstatements
or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).
-6-